Belantamab mafodotin plus venetoclax in t(11;14)-positive relapsed or refractory multiple myeloma - the BELI(E)VE trial

Background

Multiple myeloma (MM) is a widely incurable B-cell malignancy that predominantly affects older adults, representing 10% of hematologic cancers. Despite advancements in therapy that have significantly extended median overall survival (OS), MM remains a clinical challenge with poor prognosis for patients refractory to multiple drug classes. There is a critical need for innovative and personalized treatments, including for patients with translocation (11;14), a subgroup characterized by specific therapeutic vulnerabilities. Combined targeting of B-cell maturation antigen (BCMA) and BCL-2 presents a promising personalized treatment strategy for inducing deep remissions and improving outcomes in this specific subgroup.